“Ozenoxacin, a Novel, Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients with Impetigo: Phase III Clinical Trials Pooled Analysis Results”, J of Skin, vol. 1, no. 3.1, p. s102, Oct. 2017, doi: 10.25251/skin.1.supp.101.